FOR IMMEDIATE RELEASE

EARNINGS RELEASE
Date: May 31, 2021

Advanced Enzyme Technologies Limited announces Financial Results for Fourth Quarter and Year ended March 2021

Mumbai, India: Saturday, May 29, 2021 – Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for fourth quarter and full year ended March 2021.

CONSOLIDATED FINANCIAL RESULTS:

(Amount in INR Mn.)	Q4 FY21	Q3 FY21	Q4 FY20	Change (Y-o-Y %)	FY21	FY20	Change (%)
Revenue	1,332	1,377	1,103	21	5,018	4,440	13
EBITDA	549	664	487	13	2,315	2,023	14
EBITDA Margin (%)	41	48	44		46	46	
PAT	338	443	327	3	1,515	1,330	14
PAT Margin (%)	25	32	29		30	30	
EPS	2.84	3.86	2.81		13.09	11.58	

CONSOLIDATED FINANCIAL HIGHLIGHTS:

Q4FY21 VS Q4FY20:

- Q4FY21 Sales up 21% YoY to INR 1,332 mn against INR 1,103 mn in Q4FY20
- EBITDA for Q4FY21 stands at INR 549 mn against INR 487 mn in Q4FY20, up 13%
- EBITDA Margin for Q4FY21 stands at 41% as against 44% in Q4FY20
- Q4FY21 Net Profit rise by 3% at INR 338 mn against INR 327 mn in Q4FY20

FY21 VS FY20:

- FY21 Sales up 13% YoY to INR 5,018 mn against INR 4,440 mn in FY20
- EBITDA for FY21 stands at INR 2,315 mn against INR 2,023 mn in FY20, up 14%
- EBITDA Margin for FY21 stands at 46% as against 46% in FY20
- FY21 Net Profit rise by 14% at INR 1,515 mn against INR 1,330 mn in FY20

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue Annual Review:

(

About Advanced Enzyme Technologies Limited

Advanced Enzyme Technologies Limited, incorporated in 1989, is a research driven company with global leadership in the manufacturing of enzymes and probiotics. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.

Equipped with state-of-the-art 7 manufacturing facilities and 6 research & development locations across India, Germany and US, Advanced Enzymes exports to 45+ countries across 6 continents, and provides customized & effective enzyme solutions coupled with the best in technical advice & superior service.

Recently, we have acquired a company specialized in effervescent based products. This acquisition synergized us with 2 manufacturing facilities and 1 research & development facility. Now, in totality we are equipped with 9 manufacturing and 7 R&D facilities.

Advanced Enzymes has received the Bio-Excellence award for being the Best Industrial Biotech Company at Bangalore India Bio in 2010 as well as 2014. In 2013, Advanced Enzymes has also been recognised by Inc. India, as one of the top 500 fastest-growing mid-sized companies in India, Excellence in R&D at UBM India Pharma Awards 2018. Advanced Enzymes has also been recipient of the Emerging India Award in 2010, in the Life Sciences category, by CNBC TV18 and ICICI Bank. Advanced Enzymes has also been awarded for Best IPO at IR Society Awards 2017, by Investor Relation Society of India in association with BSE, KPMG India and Bloomberg.

Forward-looking statements

This press release may contain forward-looking statements with respect to Advanced Enzyme Technologies' future (financial) performance and position. Such statements are based on current expectations, estimates and information currently available to the company.

Advanced Enzyme Technologies Limited cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. The company has no obligation to update the statements contained in this press release, unless required by law.

Q4FY21

This information ma contain certain forward-looking statements/details in the current scenario, which is extremel d namic and increasingl fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events ma be materiall different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and anal sis of the information contained or referred to in this section be fore taking an action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Compan under takes no obligation to publicl update or revise an of the opinions or forward-looking statements expressed in this section, consequent to new information, future events or otherwise.

Enz me are
molecul s tha
within l ing c
all livin org
as spe alize
accelera e
biochen cal r

Advance us
replace che
improve effic
variet f inc
for its cu s om s

It i
human being is able to
take advantage of the po
Enz mes for well being and
leading



Note: Facts & Figures as on 31st March 2021

All the numbers are as per IndAs







₹ in Million

*YoY Growth







Note: 1. On Consolidated Basis
2. PAT is before minority

3. Product categorywise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.
5. Product categorywise revenue does not include SSPL numbers



Human HC Animal HC Bio-Processing



Asia (ex- India) Others India Europe USA



Human HC Animal HC Bio-Processing



Asia (ex- India) Others India Europe USA

Note: 1. On Consolidated Basis

2. EBIDTA is including other income

3. Segment-wise revenue does not include other operating income

4. Ind AS adjustments are carried out on account of commission and discount.

5. Product categorywise revenue does not include SSPL numbers







₹ in Million

*YoY Growth







Note: 1. On Consolidated Basis
2. PAT is before minority

3. Product categorywise revenue does not include other operating income and Ind AS adjustments

4. Ind AS adjustments are carried out on account of commission and discount.
5. Product categorywise revenue does not include SSPL numbers









Note: 1. On Consolidated Basis

2. EBIDTA is including other income

3. Segment-wise revenue does not include other operating income

4. Ind AS adjustments are carried out on account of commission and discount.

5. Product categorywise revenue does not include SSPL numbers

₹ in Million except per share data

		1,377	1,103	21%		4,440	13%
Expenses		778	682	27%		2,675	12%
Profit from Operations before Other Income, Finance Costs and Exceptional Item		599	421	10%		1,765	15%
Other Income		13	18	-6%		56	57%
Profit from ordinar activities before Finance Costs and Exceptional Item		612	439	10%		1,821	16%
Finance costs		3	7	-43%		30	-47%
Profit from ordinar activities before tax		609	432	11%		1,791	17%
Tax		166	105	33%		461	28%
		443	327	3%		1,330	14%
		3.86	2.81			11.58	

₹ in Million

Propert , plant and equipment		2,096
Capital work-in-progress		101
Intangible assets		592
Goodwill		2,941
Other non-current assets		251
Current assets		3,757
Assets held for sale		48
Equit share capital		223
Other equit		8,173
Non-controlling interest		278
Non-current liabilities		461
Current liabilities		596
Liabilities classified as held for sale		55

₹ in Million



CAGR=9.97%



CAGR=10.84%



CAGR=11.30%



CAGR=13.01%

Note: All the numbers are as per IndAs

All numbers are on Consolidated basis

ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth)









Note: All the numbers are as per IndAs
All numbers are on Consolidated basis
*Net working capital days =((Trade receivables + inventories – Trade payables)/ Revenue from operations)*365*
Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent

(As on 21st Ma 2021)

Market Capitalization (₹)	
Shares Outstanding	
Free Float	
Symbol (NSE/ BSE)	

ORBIMED ASIA III MAURITIUS	12.09
HDFC AMC	4.88
NALANDA INDIA EQUITY FUND	4.75
UTI MF	1.65
ICICI PRUDENTIAL MF	0.63

(As on 21st Ma 2021)

Source: NSE



Note: Data mentioned in above chart is as on 31st March 2021

5th Floor, 'A' wing, Sun Magnetica
LIC Service Road, Louiswadi
Thane (W) 400 604, India
Tel: +91-22-4170 3200
Fax: + 91-22-25835159